


ICON8 Trials Programme

ICON8 Accrual



Final recruitment figure = 1566

ICON8 pathway closed to recruitment 28th November 2014

Anticipate PFS analysis Q4 2016, OS analysis Q4 2018

ICON8 trials programme

N=1485

ICON8

Stage IC-IV EOC/PPC/FTC

Randomise 1:1:1

Arm 1
6 cycles

Arm 2
6 cycles

Arm 3
6 cycles

| | | |
|-------|---------------------------------|-----|
| Arm 1 | Carboplatin AUC 5 | q3w |
| | Paclitaxel 175mg/m ² | q3w |

| | | |
|-------|--------------------------------|-----|
| Arm 2 | Carboplatin AUC 5 | q3w |
| | Paclitaxel 80mg/m ² | q1w |

| | | |
|-------|--------------------------------|-----|
| Arm 3 | Carboplatin AUC 2 | q1w |
| | Paclitaxel 80mg/m ² | q1w |

NB. High-risk patients remain eligible for ICON8 so that patients with contra-indications to bevacizumab and those unable to access it are still able to enter the trial

N=1170

ICON8B

High-risk* stage III-IV EOC/PPC/FTC

Randomise 1:1:1

Arm B1
6 cycles

Arm B2
6 cycles

Arm B3
6 cycles

Maintenance bevacizumab

| | | |
|--------|---------------------------------|-----|
| Arm B1 | Carboplatin AUC 5 | q3w |
| | Paclitaxel 175mg/m ² | q3w |
| | <u>Bevacizumab</u> 7.5 mg/kg | q3w |

| | | |
|--------|--------------------------------|-----|
| Arm B2 | Carboplatin AUC 5 | q3w |
| | Paclitaxel 80mg/m ² | q1w |

| | | |
|--------|--------------------------------|-----|
| Arm B3 | Carboplatin AUC 5 | q3w |
| | Paclitaxel 80mg/m ² | q1w |
| | <u>Bevacizumab</u> 7.5 mg/kg | q3w |

High-risk defined as (i) FIGO (2013) stage IIIB/C with residual disease >1cm following immediate primary surgery or planned to receive primary chemotherapy +/- delayed primary surgery and (ii) FIGO (2013) stage IV

ICON8B Progress

- NHS England's Cancer Drugs Fund have agreed to provide bevacizumab for ICON8 patients in England
- Currently awaiting final adoption of amended treatment criteria by the CDF before English sites can be activated
- MHRA and Ethics approval granted in the UK. Launch meetings held.

ICON8B Progress

- Devolved nations:
 - Wales and Scotland currently securing access to bevacizumab
- International interest from:
 - ICORG
 - GICOM
 - Switzerland